Pasithea Therapeutics Corp. Material Event - What Happened

Understanding corporate announcements can be complex. This summary breaks down recent news from Pasithea Therapeutics Corp. into clear, actionable insights for investors.

1. Event Description (What happened)

Pasithea Therapeutics Corp. recently filed an 8-K, announcing it received a notice from Nasdaq, the stock exchange where its shares trade. The company failed to meet Nasdaq's minimum $1.00 bid price requirement, indicating its stock price has traded too low for too long.

To maintain a Nasdaq listing, a company's stock price generally must remain above $1.00 per share. Pasithea's stock has traded below this threshold for an extended period, triggering this official warning.

2. Event Date/Timeline (When did it happen & What happens next)

Pasithea received this official notice on February 20, 2026. Companies typically release such announcements after market close or before market open to ensure all investors receive information simultaneously.

What happens next? Pasithea has 180 calendar days (until August 19, 2026) to resolve the issue. To regain compliance, its stock's closing bid price must be $1.00 or higher for at least 10 consecutive business days during this period. If Pasithea achieves this, Nasdaq will confirm its compliance.

If the company does not meet the $1.00 mark within the initial 180 days, it may receive an additional 180-day extension. This extension is contingent on meeting other Nasdaq listing requirements and submitting a plan to Nasdaq outlining how it intends to regain compliance, potentially through a reverse stock split. Should Pasithea fail to regain compliance even with an extension, Nasdaq will issue a delisting notice, which the company can appeal.

Pasithea has stated it is actively evaluating various strategic options to regain compliance. These typically include a reverse stock split, strategic financing or partnerships, operational updates, or cost management.

3. Context (Why did it happen)

Nasdaq Listing Rule 5550(a)(2) mandates that a company's stock maintain a minimum bid price of $1.00 per share. If a stock's closing bid price falls below $1.00 for 30 consecutive business days, the company receives a warning notice like this one.

Pasithea is a clinical-stage biotech company developing novel treatments for neurological and mental health disorders, with its lead candidate, PT-123, currently in clinical development. While its research shows promise, the biotech sector often faces significant challenges: a long, costly path to drug approval, intense competition, and the need for substantial ongoing funding. Like many early-stage biotechs, Pasithea is not yet profitable and relies heavily on investor capital. This, combined with broader market sentiment towards speculative growth stocks and the inherent risks of drug development, likely contributed to the sustained pressure on its share price.

4. Impact Assessment (Why does this matter & Who is affected)

This notice represents a serious warning for Pasithea. It does not mean immediate delisting, but it signals a significant red flag. Listing on a major exchange like Nasdaq provides a company with credibility, facilitates investor trading, and helps raise crucial capital for research and development.

If Pasithea ultimately faces delisting (removal from Nasdaq), it could:

• Erode investor confidence: Investors may become less willing to invest in a company not listed on a major exchange.
• Complicate capital raising efforts: Attracting new investors or securing loans becomes more difficult if the stock is not easily traded, potentially impacting funding for critical drug development.
• Diminish stock liquidity: Current shareholders might find it much harder to sell their stock quickly or at a fair price.

Therefore, while Pasithea's drug research may progress, this financial hurdle poses a significant concern for the company's future on the public market and its ability to bring treatments to patients.

Who is affected?

• Investors/Shareholders: This primarily concerns anyone owning Pasithea stock. Uncertainty surrounding the listing status can increase stock price volatility and potentially lead to further declines. Delisting could make trading shares significantly more difficult.
• Pasithea Management and Employees: While the notice does not directly impact daily operations or SEC reporting yet, it places immense pressure on management to resolve the issue. It could indirectly affect morale, future research funding, and the company's long-term viability if unresolved.
• Potential Future Investors: New investors may hesitate to purchase shares in a company facing delisting risks, making it harder for Pasithea to attract new capital.
• Future Patients: Ultimately, the company's ability to fund and advance its drug pipeline directly impacts its potential to deliver new treatments for neurological and mental health conditions.

5. Financial Impact

While the notice itself does not carry an immediate direct financial charge or impact on the company's current financial statements, the potential for delisting carries significant financial implications. If Pasithea were to be delisted from Nasdaq:

• It would significantly hinder the company's ability to raise capital through equity offerings. This capital is crucial for funding extensive research and development activities, including the advancement of its lead candidate, PT-123.
• It could lead to a decrease in investor confidence, potentially driving down the stock price further and making future financing more challenging and costly.
• The liquidity of the company's stock would be severely reduced, making it difficult for existing shareholders to sell their shares and potentially impacting the company's valuation.
• A diminished public market presence and perceived financial instability could also indirectly affect the company's ability to attract and retain talent, particularly in a competitive biotech landscape.
• The need to regain compliance might lead to strategic decisions, such as a reverse stock split. While a reverse split addresses the bid price, it does not fundamentally alter the company's financial health or market capitalization.

6. Key Takeaways for Investors

Here are the essential points for investors to consider:

• Serious Warning: This is a significant event. While not an immediate delisting, it places the company on a tight deadline to address its stock price and underlying financial and operational challenges.
• Potential for Reverse Stock Split: This common strategy offers a cosmetic fix for the share price but does not change the company's fundamental value. It can sometimes signal deeper market issues.
• Increased Volatility: Expect the stock to remain quite volatile as the deadline approaches and the company explores its options. News regarding their strategy or clinical pipeline will have an amplified effect.
• Monitor Closely: If you own Pasithea stock, closely track their announcements and the stock price. The next few months are critical for their Nasdaq listing status and overall financial health.
• Risk vs. Reward: This situation adds a significant layer of risk to investing in Pasithea. Beyond the immediate delisting threat, investors should remember the inherent volatility and high-risk nature of biotech investments. These include potential clinical trial failures, regulatory setbacks, intense competition, and the constant need for significant capital to fund research and development. Pasithea's ability to secure future funding and advance its pipeline will be crucial, especially under the pressure of this Nasdaq notice.

Stay informed by reviewing their official SEC filings (10-K, 10-Q, 8-K) for the most up-to-date financial and operational details.